Endotis Pharma forms a strategic alliance with Catalent Pharma Solutions for the development of synthetic oligosaccharides
Endotis Pharma announced the formation of a strategic alliance with Catalent Pharma Solutions (a worldwide leader in pharmaceutical technologies and services). The two companies will collaborate exclusively to develop certain oral formulations of small-glyco drugs and are now focusing on the preclinical development of Endotis' EP37151 compound.
EP37151 is a first in-class oral synthetic oligosaccharide anticoagulant which, as an indirect factor Xa inhibitor, acts via antithrombin activation. The companies expect to initiate a Phase I clinical trial program during the second quarter of 2010.
Maurice Petitou PhD, Head of Pre-Clinical Research and Development at Endotis Pharma, commented: "Since the initiation of our collaboration with Catalent, we have obtained exciting and self-consistent results on the oral administration of small-glyco drugs. Today, we are delighted to initiate preclinical studies with our first oral anticoagulant. The oral formulation of synthetic oligosaccharides is a major breakthrough that will allow us to fully exploit the therapeutic potential of small-glyco drugs which, to date, have only been administered intravenously or subcutaneously.”
Other news from the department business & finance
